Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21948079 | 1.00 | L3MBTL1 (0.34) | L3MBTL1MAPTALDH1A1CDC25ACDC25B | |
| SCHEMBL16766054 | 1.00 | L3MBTL1 (0.34) | L3MBTL1MAPTALDH1A1CDC25ACDC25B | |
| SCHEMBL21948078 | 1.00 | L3MBTL1 (0.34) | L3MBTL1MAPTALDH1A1CDC25ACDC25B | |
| SCHEMBL16383055 | 1.00 | L3MBTL1 (0.34) | L3MBTL1MAPTALDH1A1CDC25ACDC25B | |
| SCHEMBL16383069 | 1.00 | L3MBTL1 (0.34) | L3MBTL1MAPTALDH1A1CDC25ACDC25B | |
| SCHEMBL6127789 | 0.93 | ALDH1A1 (0.34) | L3MBTL1MAPTALDH1A1 | |
| SCHEMBL18595259 | 0.93 | ALDH1A1 (0.34) | L3MBTL1MAPTALDH1A1 | |
| SCHEMBL17037490 | 0.93 | ALDH1A1 (0.34) | L3MBTL1MAPTALDH1A1 | |
| SCHEMBL17037491 | 0.93 | ALDH1A1 (0.34) | L3MBTL1MAPTALDH1A1 | |
| SCHEMBL19043993 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242526-A1 | Deuterated Pyridopyrimidinones And Their Use As Highly Selective Cyclin-Dependent Kinase 2 Inhibitors | ZENTAUR THERAPEUTICS INTERNATIONAL LIMITED (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242526-A1 | Deuterated Pyridopyrimidinones And Their Use As Highly Selective Cyclin-Dependent Kinase 2 Inhibitors | ZENTAUR THERAPEUTICS INTERNATIONAL LIMITED (CN) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242526-A1 | Deuterated Pyridopyrimidinones And Their Use As Highly Selective Cyclin-Dependent Kinase 2 Inhibitors | CDK2, CDK4, CCNI | L3MBTL1 2938/4885MAPT 2226/4885ALDH1A1 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.